Efficacy and Safety of Apatinib Mesylate Tablets Combined with TACE and radiotherapy in the Treatment of HCC Patients with PVTT:A Prospective Study

Trial Profile

Efficacy and Safety of Apatinib Mesylate Tablets Combined with TACE and radiotherapy in the Treatment of HCC Patients with PVTT:A Prospective Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Aug 2018

At a glance

  • Drugs Rivoceranib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Mar 2018 New trial record
    • 28 Dec 2016 Recruitment completed, according to results published in the Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top